(+)-Tetrandrine increases expression ISO RGD:1350223 6480464 tetrandrine results in increased expression of MAP1LC3B CTD PMID:26822499 (-)-demecolcine increases expression ISO RGD:1350223 6480464 Demecolcine results in increased expression of MAP1LC3B mRNA CTD PMID:23649840 (-)-epigallocatechin 3-gallate multiple interactions ISO RGD:1350223 6480464 [potassium chromateVI co-treated with epigallocatechin gallate] results in increased expression of MAP1LC3B mRNA CTD PMID:22079256 (-)-epigallocatechin 3-gallate increases expression ISO RGD:1350223 6480464 epigallocatechin gallate results in increased expression of MAP1LC3B protein CTD PMID:32512070 1,2-dimethylhydrazine decreases expression ISO RGD:1551009 6480464 1, 2-Dimethylhydrazine results in decreased expression of MAP1LC3B mRNA CTD PMID:22206623 1,2-dimethylhydrazine multiple interactions ISO RGD:1551009 6480464 [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of MAP1LC3B mRNA CTD PMID:22206623 1-nitropyrene increases expression ISO RGD:1350223 6480464 1-nitropyrene results in increased expression of MAP1LC3B mRNA, 1-nitropyrene results in increased expression of MAP1LC3B protein CTD PMID:29078374 1-nitropyrene multiple interactions ISO RGD:1551009 6480464 ATG7 protein affects the reaction [1-nitropyrene results in increased expression of MAP1LC3B protein] CTD PMID:29078374 1-nitropyrene increases expression ISO RGD:1551009 6480464 1-nitropyrene results in increased expression of MAP1LC3B mRNA, 1-nitropyrene results in increased expression of MAP1LC3B protein CTD PMID:29078374 17alpha-ethynylestradiol affects expression ISO RGD:1551009 6480464 Ethinyl Estradiol affects the expression of MAP1LC3B mRNA CTD PMID:17555576 17alpha-ethynylestradiol multiple interactions ISO RGD:1551009 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in decreased expression of MAP1LC3B mRNA CTD PMID:17942748 17alpha-ethynylestradiol decreases expression ISO RGD:1551009 6480464 Ethinyl Estradiol results in decreased expression of MAP1LC3B mRNA CTD PMID:17942748 2,2',5,5'-tetrachlorobiphenyl multiple interactions ISO RGD:1350223 6480464 3-methyladenine inhibits the reaction [2 more ... CTD PMID:29518472 2,2',5,5'-tetrachlorobiphenyl increases cleavage ISO RGD:1350223 6480464 2 more ... CTD PMID:29518472 2,2',5,5'-tetrachlorobiphenyl multiple interactions EXP 6480464 3-methyladenine inhibits the reaction [2 more ... CTD PMID:29518472 2,2',5,5'-tetrachlorobiphenyl increases cleavage EXP 6480464 2 more ... CTD PMID:29518472 2,2-(2-Chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene affects expression ISO RGD:1551009 6480464 2 more ... CTD PMID:32721735 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP 6480464 Tetrachlorodibenzodioxin results in increased expression of MAP1LC3B mRNA CTD PMID:16054898 more ... 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1551009 6480464 Tetrachlorodibenzodioxin affects the expression of MAP1LC3B mRNA CTD PMID:21570461 2,3,7,8-tetrachlorodibenzodioxine affects expression EXP 6480464 Tetrachlorodibenzodioxin affects the expression of MAP1LC3B mRNA CTD PMID:22298810 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1551009 6480464 Tetrachlorodibenzodioxin results in decreased expression of MAP1LC3B mRNA CTD PMID:19770486 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1551009 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in decreased expression of MAP1LC3B mRNA CTD PMID:17942748 2,4,6-trinitrobenzenesulfonic acid increases lipidation EXP 6480464 Trinitrobenzenesulfonic Acid results in increased lipidation of MAP1LC3B protein CTD PMID:30503585 2,4,6-trinitrobenzenesulfonic acid multiple interactions EXP 6480464 Sulfur Dioxide inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased lipidation of MAP1LC3B protein] CTD PMID:30503585 2-deoxy-D-glucose multiple interactions ISO RGD:1350223 6480464 ATG7 protein promotes the reaction [Deoxyglucose results in increased prenylation of MAP1LC3B protein] more ... CTD PMID:20593179 2-deoxy-D-glucose increases prenylation ISO RGD:1350223 6480464 Deoxyglucose results in increased prenylation of MAP1LC3B protein CTD PMID:20593179 2-hydroxyethyl methacrylate increases expression ISO RGD:1350223 6480464 hydroxyethyl methacrylate results in increased expression of MAP1LC3B mRNA, hydroxyethyl methacrylate results in increased expression of MAP1LC3B protein CTD PMID:28184909 2-hydroxyethyl methacrylate multiple interactions ISO RGD:1350223 6480464 3-4-methylphenylsulfonyl-2-propenenitrile inhibits the reaction [hydroxyethyl methacrylate results in increased expression of MAP1LC3B mRNA], 3-4-methylphenylsulfonyl-2-propenenitrile inhibits the reaction [hydroxyethyl methacrylate results in increased expression of MAP1LC3B protein] CTD PMID:28184909 3,3',5-triiodo-L-thyronine increases expression ISO RGD:1551009 6480464 Triiodothyronine results in increased expression of MAP1LC3B mRNA CTD PMID:30209975 3,3',5-triiodo-L-thyronine increases lipidation ISO RGD:1551009 6480464 Triiodothyronine results in increased lipidation of MAP1LC3B protein CTD PMID:30209975 3,3',5-triiodo-L-thyronine multiple interactions ISO RGD:1551009 6480464 bafilomycin A1 promotes the reaction [Triiodothyronine results in increased lipidation of MAP1LC3B protein], Triiodothyronine promotes the reaction [bafilomycin A1 results in increased lipidation of MAP1LC3B protein] CTD PMID:30209975 3,4-methylenedioxymethamphetamine increases expression EXP 6480464 N-Methyl-3, 4-methylenedioxyamphetamine results in increased expression of MAP1LC3B mRNA CTD PMID:30071829 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid multiple interactions ISO RGD:1350223 6480464 MK-886 inhibits the reaction [Arsenic Trioxide results in increased cleavage of MAP1LC3B protein] CTD PMID:30677399 3-methyladenine multiple interactions EXP 6480464 3-methyladenine inhibits the reaction [2 more ... CTD PMID:18640276 more ... 3-methyladenine decreases expression EXP 6480464 3-methyladenine results in decreased expression of MAP1LC3B mRNA CTD PMID:30611790 3-methyladenine decreases cleavage ISO RGD:1551009 6480464 3-methyladenine results in decreased cleavage of MAP1LC3B protein CTD PMID:26804720 3-methyladenine affects metabolic processing ISO RGD:1350223 6480464 3-methyladenine affects the metabolism of MAP1LC3B protein CTD PMID:23680031 3-methyladenine multiple interactions ISO RGD:1551009 6480464 3-methyladenine inhibits the reaction [Cadmium Chloride results in increased expression of MAP1LC3B protein alternative form] more ... CTD PMID:21325019 more ... 3-methyladenine multiple interactions ISO RGD:1350223 6480464 3-methyladenine inhibits the reaction [2 more ... CTD PMID:20962572 more ... 3-methyladenine decreases expression ISO RGD:1551009 6480464 3-methyladenine results in decreased expression of MAP1LC3B mRNA, 3-methyladenine results in decreased expression of MAP1LC3B protein modified form CTD PMID:21681844 , PMID:32512069 3-Nitrofluoranthene increases expression ISO RGD:1551009 6480464 3-nitrofluoranthene results in increased expression of MAP1LC3B protein CTD PMID:19041363 3H-1,2-dithiole-3-thione decreases expression EXP 6480464 1, 2-dithiol-3-thione results in decreased expression of MAP1LC3B mRNA CTD PMID:19162173 4,4'-diaminodiphenylmethane decreases expression ISO RGD:1551009 6480464 4, 4'-diaminodiphenylmethane results in decreased expression of MAP1LC3B mRNA CTD PMID:18648102 4-hydroxynon-2-enal increases expression ISO RGD:1551009 6480464 4-hydroxy-2-nonenal results in increased expression of MAP1LC3B mRNA CTD PMID:19191707 4-hydroxyphenyl retinamide increases expression ISO RGD:1350223 6480464 Fenretinide results in increased expression of MAP1LC3B mRNA CTD PMID:16671099 4-hydroxyphenyl retinamide increases expression ISO RGD:1551009 6480464 Fenretinide results in increased expression of MAP1LC3B mRNA CTD PMID:28973697 4-phenylbutyric acid multiple interactions ISO RGD:1551009 6480464 4-phenylbutyric acid inhibits the reaction [Dibutyl Phthalate results in increased cleavage of MAP1LC3B protein] CTD PMID:26804720 4-phenylbutyric acid multiple interactions ISO RGD:1350223 6480464 4-phenylbutyric acid inhibits the reaction [flavokawain B results in increased expression of MAP1LC3B protein modified form] CTD PMID:30025493 4-phenylbutyric acid multiple interactions EXP 6480464 4-phenylbutyric acid inhibits the reaction [Dibutyl Phthalate results in increased cleavage of MAP1LC3B protein] CTD PMID:26804720 5-aza-2'-deoxycytidine multiple interactions ISO RGD:1350223 6480464 Decitabine inhibits the reaction [Rotenone results in increased lipidation of and results in increased cleavage of MAP1LC3B protein], Decitabine inhibits the reaction [sodium arsenite results in increased expression of MAP1LC3B protein] CTD PMID:19577553 , PMID:30673822 5-fluorouracil affects response to substance ISO RGD:1350223 6480464 MAP1LC3B protein affects the susceptibility to Fluorouracil CTD PMID:15548681 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide multiple interactions ISO RGD:1350223 6480464 6-chloro-2 more ... CTD PMID:24145604 7-ketocholesterol increases expression ISO RGD:1551009 6480464 7-ketocholesterol results in increased expression of MAP1LC3B protein CTD PMID:24445604 7-ketocholesterol multiple interactions ISO RGD:1551009 6480464 CD38 gene mutant form promotes the reaction [7-ketocholesterol results in increased expression of MAP1LC3B protein] CTD PMID:24445604 acadesine multiple interactions ISO RGD:1350223 6480464 acadesine promotes the reaction [Artesunate results in increased lipidation of MAP1LC3B protein] CTD PMID:33002460 acetaldehyde increases lipidation ISO RGD:1551009 6480464 Acetaldehyde results in increased lipidation of MAP1LC3B protein CTD PMID:24492484 acetaldehyde multiple interactions ISO RGD:1551009 6480464 Cyanamide promotes the reaction [Acetaldehyde results in increased lipidation of MAP1LC3B protein] CTD PMID:24492484 acetamide decreases expression EXP 6480464 acetamide results in decreased expression of MAP1LC3B mRNA CTD PMID:31881176 acrylamide decreases expression EXP 6480464 Acrylamide results in decreased expression of MAP1LC3B mRNA CTD PMID:28959563 acrylamide increases expression ISO RGD:1350223 6480464 Acrylamide results in increased expression of MAP1LC3B mRNA CTD PMID:32763439 actinomycin D multiple interactions ISO RGD:1551009 6480464 Dactinomycin inhibits the reaction [Ethanol results in increased expression of MAP1LC3B protein] CTD PMID:24095927 aflatoxin B1 increases expression ISO RGD:1350223 6480464 Aflatoxin B1 results in increased expression of MAP1LC3B mRNA CTD PMID:27153756 aldehydo-D-glucose multiple interactions EXP 6480464 3-methyladenine inhibits the reaction [N-1 more ... CTD PMID:29128638 aldehydo-D-glucose decreases expression EXP 6480464 Glucose results in decreased expression of MAP1LC3B protein CTD PMID:29128638 aldrin decreases expression ISO RGD:1551009 6480464 Aldrin results in decreased expression of MAP1LC3B mRNA CTD PMID:18579281 all-trans-retinoic acid multiple interactions ISO RGD:1350223 6480464 ATG5 protein affects the reaction [Tretinoin results in increased metabolism of and affects the localization of MAP1LC3B protein] more ... CTD PMID:28978663 , PMID:29743969 all-trans-retinoic acid increases expression ISO RGD:1350223 6480464 Tretinoin results in increased expression of MAP1LC3B mRNA CTD PMID:29743969 aloxistatin multiple interactions ISO RGD:1551009 6480464 [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form] more ... CTD PMID:27635674 aloxistatin multiple interactions ISO RGD:1350223 6480464 [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form] more ... CTD PMID:27635674 alpha,alpha-trehalose increases cleavage ISO RGD:1551009 6480464 Trehalose results in increased cleavage of MAP1LC3B protein CTD PMID:29486218 amiodarone increases lipidation ISO RGD:1350223 6480464 Amiodarone results in increased lipidation of MAP1LC3B protein CTD PMID:32651653 ammonium chloride affects expression EXP 6480464 Ammonium Chloride affects the expression of MAP1LC3B mRNA CTD PMID:16483693 ammonium chloride increases expression ISO RGD:1551009 6480464 Ammonium Chloride results in increased expression of MAP1LC3B protein modified form CTD PMID:31310755 ammonium chloride increases metabolic processing ISO RGD:1350223 6480464 Ammonium Chloride results in increased metabolism of MAP1LC3B protein CTD PMID:29908302 ammonium chloride multiple interactions ISO RGD:1350223 6480464 bafilomycin A1 affects the reaction [Ammonium Chloride results in increased metabolism of MAP1LC3B protein], NR1I2 protein affects the reaction [Ammonium Chloride results in increased metabolism of MAP1LC3B protein] CTD PMID:29908302 ammonium chloride increases lipidation ISO RGD:1350223 6480464 Ammonium Chloride results in increased lipidation of MAP1LC3B protein CTD PMID:31927068 amphotericin B increases expression ISO RGD:1551009 6480464 Amphotericin B results in increased expression of MAP1LC3B protein CTD PMID:23988732 apigenin multiple interactions ISO RGD:1350223 6480464 Acetylcysteine inhibits the reaction [Apigenin results in increased expression of MAP1LC3B protein modified form], Glutathione inhibits the reaction [Apigenin results in increased expression of MAP1LC3B protein modified form] CTD PMID:29247770 apigenin increases expression ISO RGD:1350223 6480464 Apigenin results in increased expression of MAP1LC3B protein modified form CTD PMID:29247770 apocynin multiple interactions EXP 6480464 acetovanillone analog inhibits the reaction [Chlorpyrifos results in increased lipidation of MAP1LC3B protein] CTD PMID:29859868 arsane increases expression ISO RGD:1350223 6480464 Arsenic results in increased expression of MAP1LC3B protein, Arsenic results in increased expression of MAP1LC3B protein modified form CTD PMID:27413109 , PMID:29248574 arsane multiple interactions EXP 6480464 [[sodium arsenite results in increased abundance of Arsenic] co-treated with [Sodium Fluoride results in increased abundance of Fluorides]] results in increased expression of MAP1LC3B mRNA, [sodium arsenite results in increased abundance of Arsenic] which results in increased expression of MAP1LC3B mRNA CTD PMID:31844926 arsane multiple interactions ISO RGD:1350223 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of and results in increased lipidation of MAP1LC3B protein more ... CTD PMID:29248574 , PMID:32525701 arsane increases expression ISO RGD:1551009 6480464 Arsenic results in increased expression of MAP1LC3B protein CTD PMID:27413109 arsenic atom increases expression ISO RGD:1350223 6480464 Arsenic results in increased expression of MAP1LC3B protein, Arsenic results in increased expression of MAP1LC3B protein modified form CTD PMID:27413109 , PMID:29248574 arsenic atom multiple interactions EXP 6480464 [[sodium arsenite results in increased abundance of Arsenic] co-treated with [Sodium Fluoride results in increased abundance of Fluorides]] results in increased expression of MAP1LC3B mRNA, [sodium arsenite results in increased abundance of Arsenic] which results in increased expression of MAP1LC3B mRNA CTD PMID:31844926 arsenic atom multiple interactions ISO RGD:1350223 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of and results in increased lipidation of MAP1LC3B protein more ... CTD PMID:29248574 , PMID:32525701 arsenic atom increases expression ISO RGD:1551009 6480464 Arsenic results in increased expression of MAP1LC3B protein CTD PMID:27413109 arsenous acid multiple interactions EXP 6480464 MAP1LC3B protein affects the reaction [Arsenic Trioxide results in decreased expression of SQSTM1 protein], MAP1LC3B protein affects the reaction [Arsenic Trioxide results in increased lipidation of MAP1LC3B protein] CTD PMID:29111283 arsenous acid increases cleavage ISO RGD:1350223 6480464 Arsenic Trioxide results in increased cleavage of MAP1LC3B protein CTD PMID:30677399 arsenous acid multiple interactions ISO RGD:1350223 6480464 3-methyladenine inhibits the reaction [Arsenic Trioxide results in increased cleavage of MAP1LC3B protein] more ... CTD PMID:28978663 more ... arsenous acid increases expression ISO RGD:1350223 6480464 Arsenic Trioxide results in increased expression of MAP1LC3B mRNA, Arsenic Trioxide results in increased expression of MAP1LC3B protein CTD PMID:29307831 more ... arsenous acid increases expression ISO RGD:1551009 6480464 Arsenic Trioxide results in increased expression of MAP1LC3B mRNA, Arsenic Trioxide results in increased expression of MAP1LC3B protein CTD PMID:30032600 more ... arsenous acid increases lipidation EXP 6480464 Arsenic Trioxide results in increased lipidation of MAP1LC3B protein CTD PMID:29111283 arsenous acid multiple interactions ISO RGD:1551009 6480464 Taurine inhibits the reaction [Arsenic Trioxide results in increased cleavage of MAP1LC3B protein], Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of MAP1LC3B protein] CTD PMID:30237538 , PMID:30677399 arsenous acid increases lipidation ISO RGD:1551009 6480464 Arsenic Trioxide results in increased lipidation of MAP1LC3B protein CTD PMID:29111283 arsenous acid increases cleavage ISO RGD:1551009 6480464 Arsenic Trioxide results in increased cleavage of MAP1LC3B protein CTD PMID:30677399 artesunate multiple interactions ISO RGD:1350223 6480464 3-methyladenine inhibits the reaction [Artesunate results in increased lipidation of MAP1LC3B protein] more ... CTD PMID:33002460 artesunate increases lipidation ISO RGD:1350223 6480464 Artesunate results in increased lipidation of MAP1LC3B protein CTD PMID:33002460 atazanavir sulfate increases expression ISO RGD:1350223 6480464 Atazanavir Sulfate results in increased expression of MAP1LC3B mRNA CTD PMID:32152650 atazanavir sulfate multiple interactions ISO RGD:1350223 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA CTD PMID:32152650 auramine O multiple interactions ISO RGD:1350223 6480464 ALDH1A1 protein promotes the reaction [Benzophenoneidum results in increased lipidation of and results in increased cleavage of MAP1LC3B protein], Benzophenoneidum results in increased lipidation of and results in increased cleavage of MAP1LC3B protein CTD PMID:28722353 AZD4547 multiple interactions ISO RGD:1350223 6480464 bafilomycin A1 affects the reaction [AZD4547 affects the expression of MAP1LC3B protein modified form] CTD PMID:26853465 AZD4547 affects expression ISO RGD:1350223 6480464 AZD4547 affects the expression of MAP1LC3B protein modified form CTD PMID:26853465 bafilomycin A1 increases expression ISO RGD:1350223 6480464 bafilomycin A1 results in increased expression of MAP1LC3B protein more ... CTD PMID:24145604 more ... bafilomycin A1 increases lipidation EXP 6480464 bafilomycin A1 results in increased lipidation of MAP1LC3B protein CTD PMID:32525084 bafilomycin A1 multiple interactions EXP 6480464 [Doxorubicin co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein more ... CTD PMID:32278738 , PMID:32525084 bafilomycin A1 increases expression EXP 6480464 bafilomycin A1 results in increased expression of MAP1LC3B protein modified form CTD PMID:32278738 bafilomycin A1 multiple interactions ISO RGD:1551009 6480464 bafilomycin A1 promotes the reaction [Triiodothyronine results in increased lipidation of MAP1LC3B protein], Triiodothyronine promotes the reaction [bafilomycin A1 results in increased lipidation of MAP1LC3B protein] CTD PMID:30209975 bafilomycin A1 increases lipidation ISO RGD:1551009 6480464 bafilomycin A1 results in increased lipidation of MAP1LC3B protein CTD PMID:30209975 bafilomycin A1 increases expression ISO RGD:1551009 6480464 bafilomycin A1 results in increased expression of MAP1LC3B protein modified form CTD PMID:31310755 bafilomycin A1 increases cleavage ISO RGD:1350223 6480464 bafilomycin A1 results in increased cleavage of MAP1LC3B protein CTD PMID:29248574 bafilomycin A1 decreases degradation EXP 6480464 bafilomycin A1 results in decreased degradation of MAP1LC3B protein modified form CTD PMID:26459185 bafilomycin A1 multiple interactions ISO RGD:1350223 6480464 [di-2-pyridylketone-4 more ... CTD PMID:23880069 more ... belinostat increases expression ISO RGD:1350223 6480464 belinostat results in increased expression of MAP1LC3B mRNA CTD PMID:19606018 benzo[a]pyrene increases expression ISO RGD:1350223 6480464 Benzoapyrene results in increased expression of MAP1LC3B mRNA CTD PMID:22316170 benzo[a]pyrene increases lipidation EXP 6480464 Benzoapyrene results in increased lipidation of MAP1LC3B protein CTD PMID:32619457 benzo[a]pyrene multiple interactions EXP 6480464 [Benzoapyrene co-treated with Resveratrol] promotes the reaction [MAP1LC3B protein binds to TOMM20 protein] more ... CTD PMID:32619457 benzo[a]pyrene increases expression ISO RGD:1551009 6480464 Benzoapyrene results in increased expression of MAP1LC3B mRNA CTD PMID:22228805 benzo[a]pyrene diol epoxide I increases expression ISO RGD:1350223 6480464 7 more ... CTD PMID:19150397 , PMID:20382639 beta-lapachone multiple interactions ISO RGD:1350223 6480464 beta-lapachone affects the localization of and results in increased metabolism of MAP1LC3B protein CTD PMID:21035436 betulinic acid increases expression ISO RGD:1350223 6480464 betulinic acid results in increased expression of MAP1LC3B protein modified form CTD PMID:30136359 betulinic acid multiple interactions ISO RGD:1350223 6480464 Erlotinib Hydrochloride promotes the reaction [betulinic acid results in increased expression of MAP1LC3B protein modified form] CTD PMID:30136359 bisphenol A affects expression EXP 6480464 bisphenol A affects the expression of MAP1LC3B mRNA CTD PMID:25181051 bisphenol A affects expression ISO RGD:1350223 6480464 bisphenol A affects the expression of MAP1LC3B mRNA CTD PMID:30903817 bisphenol A increases expression ISO RGD:1350223 6480464 bisphenol A results in increased expression of MAP1LC3B protein CTD PMID:29275510 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of MAP1LC3B protein modified form CTD PMID:27539358 bisphenol A increases methylation ISO RGD:1551009 6480464 bisphenol A results in increased methylation of MAP1LC3B promoter CTD PMID:27312807 bleomycin A2 increases expression ISO RGD:1551009 6480464 Bleomycin results in increased expression of MAP1LC3B protein modified form CTD PMID:31302203 bleomycin A2 multiple interactions ISO RGD:1551009 6480464 Soot inhibits the reaction [Bleomycin results in increased expression of MAP1LC3B protein modified form] CTD PMID:31302203 bortezomib multiple interactions ISO RGD:1350223 6480464 MAP1LC3B protein affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein] CTD PMID:24085292 buspirone increases expression EXP 6480464 Buspirone results in increased expression of MAP1LC3B mRNA CTD PMID:24136188 butanal increases expression ISO RGD:1350223 6480464 butyraldehyde results in increased expression of MAP1LC3B mRNA CTD PMID:26079696 C60 fullerene increases expression EXP 6480464 fullerene C60 results in increased expression of MAP1LC3B mRNA CTD PMID:19167457 cadmium atom increases expression ISO RGD:1551009 6480464 Cadmium results in increased expression of MAP1LC3B mRNA, Cadmium results in increased expression of MAP1LC3B protein modified form CTD PMID:19126599 , PMID:27492225 cadmium atom multiple interactions ISO RGD:1350223 6480464 [Cadmium Chloride results in increased abundance of Cadmium] which results in increased metabolism of MAP1LC3B protein more ... CTD PMID:31319114 cadmium atom affects localization ISO RGD:1551009 6480464 Cadmium affects the localization of MAP1LC3B protein CTD PMID:29111403 cadmium atom multiple interactions ISO RGD:1551009 6480464 [Cadmium Chloride results in increased abundance of Cadmium] which results in increased lipidation of MAP1LC3B protein more ... CTD PMID:27492225 , PMID:31862506 cadmium dichloride multiple interactions ISO RGD:1551009 6480464 3-methyladenine inhibits the reaction [Cadmium Chloride results in increased expression of MAP1LC3B protein alternative form] more ... CTD PMID:21325019 more ... cadmium dichloride multiple interactions ISO RGD:1350223 6480464 2-aminoethoxydiphenyl borate inhibits the reaction [Cadmium Chloride results in increased expression of MAP1LC3B protein modified form] more ... CTD PMID:25639782 , PMID:31319114 cadmium dichloride increases cleavage ISO RGD:1551009 6480464 Cadmium Chloride results in increased cleavage of MAP1LC3B protein CTD PMID:29486218 cadmium dichloride increases expression ISO RGD:1350223 6480464 Cadmium Chloride results in increased expression of MAP1LC3B protein modified form CTD PMID:25639782 cadmium dichloride increases expression EXP 6480464 Cadmium Chloride results in increased expression of MAP1LC3B protein alternative form CTD PMID:21325019 cadmium dichloride increases expression ISO RGD:1551009 6480464 Cadmium Chloride results in increased expression of MAP1LC3B protein alternative form CTD PMID:21325019 caffeine multiple interactions ISO RGD:1551009 6480464 3-2 more ... CTD PMID:30555576 caffeine increases cleavage ISO RGD:1350223 6480464 Caffeine results in increased cleavage of MAP1LC3B protein CTD PMID:30555576 caffeine increases cleavage ISO RGD:1551009 6480464 Caffeine results in increased cleavage of MAP1LC3B protein CTD PMID:30555576 caffeine multiple interactions ISO RGD:1350223 6480464 2-4-2-carboxyethylphenethylamino-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in increased cleavage of MAP1LC3B protein] more ... CTD PMID:30555576 calix[6]arene increases expression ISO RGD:1350223 6480464 calix6arene results in increased expression of MAP1LC3B protein modified form CTD PMID:23872419 Calpeptin multiple interactions ISO RGD:1350223 6480464 calpeptin inhibits the reaction [dehydroeburicoic acid affects the localization of MAP1LC3B protein], calpeptin inhibits the reaction [dehydroeburicoic acid promotes the reaction [MAP1LC3B protein binds to phosphatidylethanolamine]] CTD PMID:19848398 carbon disulfide decreases expression ISO RGD:1551009 6480464 Carbon Disulfide results in decreased expression of MAP1LC3B mRNA, Carbon Disulfide results in decreased expression of MAP1LC3B protein CTD PMID:31369747 carbon disulfide multiple interactions ISO RGD:1551009 6480464 N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in decreased expression of MAP1LC3B mRNA], N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in decreased expression of MAP1LC3B protein] CTD PMID:31369747 carbon nanotube increases expression ISO RGD:1350223 6480464 Nanotubes, Carbon results in increased expression of MAP1LC3B protein CTD PMID:24389112 carbon nanotube increases expression ISO RGD:1551009 6480464 Nanotubes more ... CTD PMID:24929217 , PMID:25620056 carbon nanotube decreases expression ISO RGD:1551009 6480464 Nanotubes more ... CTD PMID:25554681 carglumic acid multiple interactions ISO RGD:1551009 6480464 N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in decreased expression of MAP1LC3B mRNA], N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in decreased expression of MAP1LC3B protein] CTD PMID:31369747 celecoxib multiple interactions ISO RGD:1350223 6480464 MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein] more ... CTD PMID:20104024 CGS-21680 multiple interactions ISO RGD:1350223 6480464 2-4-2-carboxyethylphenethylamino-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in increased cleavage of MAP1LC3B protein] CTD PMID:30555576 chenodeoxycholic acid increases expression ISO RGD:1551009 6480464 Chenodeoxycholic Acid results in increased expression of MAP1LC3B protein CTD PMID:24189133 chenodeoxycholic acid multiple interactions ISO RGD:1350223 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA more ... CTD PMID:32152650 chloropicrin increases expression ISO RGD:1350223 6480464 chloropicrin results in increased expression of MAP1LC3B mRNA CTD PMID:26352163 chloroquine multiple interactions ISO RGD:1551009 6480464 [Ethanol co-treated with Chloroquine] results in increased lipidation of MAP1LC3B protein more ... CTD PMID:24492484 more ... chloroquine increases expression ISO RGD:1551009 6480464 Chloroquine results in increased expression of MAP1LC3B protein, Chloroquine results in increased expression of MAP1LC3B protein modified form CTD PMID:25884947 , PMID:31310755 chloroquine affects localization ISO RGD:1551009 6480464 Chloroquine affects the localization of MAP1LC3B protein CTD PMID:30208301 chloroquine increases cleavage ISO RGD:1350223 6480464 Chloroquine results in increased cleavage of MAP1LC3B protein CTD PMID:29248574 chloroquine multiple interactions EXP 6480464 Chloroquine promotes the reaction [Cisplatin results in increased expression of MAP1LC3B protein modified form] more ... CTD PMID:29476062 , PMID:32937103 chloroquine increases lipidation ISO RGD:1350223 6480464 Chloroquine results in increased lipidation of MAP1LC3B protein CTD PMID:23880069 more ... chloroquine increases expression EXP 6480464 Chloroquine results in increased expression of MAP1LC3B mRNA more ... CTD PMID:17643062 more ... chloroquine increases expression ISO RGD:1350223 6480464 Chloroquine results in increased expression of MAP1LC3B mRNA more ... CTD PMID:24095927 more ... chloroquine multiple interactions ISO RGD:1350223 6480464 [Chloroquine co-treated with flavokawain B] results in increased expression of MAP1LC3B protein modified form more ... CTD PMID:23880069 more ... chloroquine increases lipidation ISO RGD:1551009 6480464 Chloroquine results in increased lipidation of MAP1LC3B protein CTD PMID:24492484 , PMID:30301768 chlorpyrifos increases lipidation EXP 6480464 Chlorpyrifos results in increased lipidation of MAP1LC3B protein CTD PMID:29859868 chlorpyrifos multiple interactions EXP 6480464 acetovanillone analog inhibits the reaction [Chlorpyrifos results in increased lipidation of MAP1LC3B protein], STAT1 protein affects the reaction [Chlorpyrifos results in increased lipidation of MAP1LC3B protein] CTD PMID:29859868 cholesterol increases expression ISO RGD:1350223 6480464 Cholesterol results in increased expression of MAP1LC3B protein modified form CTD PMID:28275691 cholesterol multiple interactions ISO RGD:1551009 6480464 Cholesterol inhibits the reaction [Cadmium Chloride results in increased cleavage of MAP1LC3B protein] CTD PMID:29486218 cholic acid increases expression ISO RGD:1551009 6480464 Cholic Acid results in increased expression of MAP1LC3B protein CTD PMID:24189133 chromium(6+) increases expression ISO RGD:1350223 6480464 chromium hexavalent ion results in increased expression of MAP1LC3B mRNA CTD PMID:30690063 chrysin multiple interactions EXP 6480464 chrysin inhibits the reaction [Acetaminophen results in increased expression of MAP1LC3B protein], chrysin inhibits the reaction [Colistin results in increased expression of MAP1LC3B protein] CTD PMID:28682524 , PMID:30273961 ciguatoxin CTX1B affects expression ISO RGD:1551009 6480464 Ciguatoxins affects the expression of MAP1LC3B mRNA CTD PMID:18353800 cisplatin multiple interactions ISO RGD:1350223 6480464 [Cisplatin results in increased phosphorylation of TP63 protein alternative form] which results in increased expression of MAP1LC3B protein more ... CTD PMID:21191146 more ... cisplatin increases expression ISO RGD:1551009 6480464 Cisplatin results in increased expression of MAP1LC3B protein, Cisplatin results in increased expression of MAP1LC3B protein modified form CTD PMID:29476062 , PMID:31306688 cisplatin multiple interactions ISO RGD:1551009 6480464 ATG7 gene mutant form inhibits the reaction [Cisplatin results in increased expression of MAP1LC3B protein modified form] more ... CTD PMID:29476062 , PMID:31306688 cisplatin increases expression EXP 6480464 Cisplatin results in increased expression of MAP1LC3B protein modified form CTD PMID:29476062 cisplatin multiple interactions EXP 6480464 Chloroquine promotes the reaction [Cisplatin results in increased expression of MAP1LC3B protein modified form] CTD PMID:29476062 cisplatin increases expression ISO RGD:1350223 6480464 Cisplatin results in increased expression of MAP1LC3B mRNA more ... CTD PMID:19561079 more ... Citreoviridin multiple interactions EXP 6480464 Rosiglitazone inhibits the reaction [citreoviridin results in increased expression of MAP1LC3B protein modified form] more ... CTD PMID:31419397 Citreoviridin increases expression ISO RGD:1551009 6480464 citreoviridin results in increased expression of MAP1LC3B protein modified form CTD PMID:31419397 Citreoviridin increases expression EXP 6480464 citreoviridin results in increased expression of MAP1LC3B protein modified form CTD PMID:31419397 Citreoviridin multiple interactions ISO RGD:1551009 6480464 Sodium Selenite inhibits the reaction [citreoviridin results in increased expression of MAP1LC3B protein modified form], Thiamine inhibits the reaction [citreoviridin results in increased expression of MAP1LC3B protein modified form] CTD PMID:31419397 clobetasol increases expression ISO RGD:1551009 6480464 Clobetasol results in increased expression of MAP1LC3B mRNA CTD PMID:27462272 clofibrate decreases expression ISO RGD:1551009 6480464 Clofibrate results in decreased expression of MAP1LC3B mRNA CTD PMID:17585979 clofibrate increases expression EXP 6480464 Clofibrate results in increased expression of MAP1LC3B mRNA CTD PMID:21318169 cobalt dichloride increases expression ISO RGD:1350223 6480464 cobaltous chloride results in increased expression of MAP1LC3B mRNA CTD PMID:19320972 , PMID:19376846 colistin multiple interactions EXP 6480464 chrysin inhibits the reaction [Colistin results in increased expression of MAP1LC3B protein] CTD PMID:30273961 colistin increases expression EXP 6480464 Colistin results in increased expression of MAP1LC3B protein CTD PMID:30273961 copper atom multiple interactions ISO RGD:1350223 6480464 [Disulfiram binds to Copper] which results in decreased expression of MAP1LC3B mRNA more ... CTD PMID:20971185 more ... copper atom multiple interactions ISO RGD:1551009 6480464 [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MAP1LC3B mRNA more ... CTD PMID:15467011 , PMID:31491480 copper(0) multiple interactions ISO RGD:1350223 6480464 [Disulfiram binds to Copper] which results in decreased expression of MAP1LC3B mRNA more ... CTD PMID:20971185 more ... copper(0) multiple interactions ISO RGD:1551009 6480464 [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MAP1LC3B mRNA more ... CTD PMID:15467011 , PMID:31491480 copper(II) chloride increases expression ISO RGD:1350223 6480464 cupric chloride results in increased expression of MAP1LC3B mRNA CTD PMID:17211630 copper(II) chloride multiple interactions ISO RGD:1551009 6480464 Acetylcysteine inhibits the reaction [cupric chloride results in increased expression of MAP1LC3B protein modified form] more ... CTD PMID:32512069 copper(II) chloride increases expression ISO RGD:1551009 6480464 cupric chloride results in increased expression of MAP1LC3B protein modified form CTD PMID:32512069 copper(II) sulfate increases expression ISO RGD:1350223 6480464 Copper Sulfate results in increased expression of MAP1LC3B mRNA CTD PMID:19549813 copper(II) sulfate multiple interactions ISO RGD:1551009 6480464 [Copper Sulfate results in increased abundance of Copper] which results in increased expression of MAP1LC3B mRNA, [Copper Sulfate results in increased abundance of Copper] which results in increased expression of MAP1LC3B protein CTD PMID:31491480 coumestrol decreases expression ISO RGD:1350223 6480464 Coumestrol results in decreased expression of MAP1LC3B mRNA CTD PMID:19167446 crocidolite asbestos decreases expression ISO RGD:1551009 6480464 Asbestos, Crocidolite results in decreased expression of MAP1LC3B mRNA CTD PMID:29279043 Cryptotanshinone multiple interactions ISO RGD:1350223 6480464 Acetylcysteine inhibits the reaction [cryptotanshinone results in increased expression of MAP1LC3B protein] more ... CTD PMID:28600121 Cryptotanshinone increases expression ISO RGD:1350223 6480464 cryptotanshinone results in increased expression of MAP1LC3B protein CTD PMID:28600121 cyanamide multiple interactions ISO RGD:1551009 6480464 Cyanamide promotes the reaction [Acetaldehyde results in increased lipidation of MAP1LC3B protein] CTD PMID:24492484 cyanamide increases lipidation ISO RGD:1551009 6480464 Cyanamide results in increased lipidation of MAP1LC3B protein CTD PMID:24492484 cyclosporin A increases expression ISO RGD:1350223 6480464 Cyclosporine results in increased expression of MAP1LC3B mRNA CTD PMID:20106945 more ... cyclosporin A multiple interactions ISO RGD:1350223 6480464 [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA CTD PMID:32152650 D-glucose multiple interactions EXP 6480464 3-methyladenine inhibits the reaction [N-1 more ... CTD PMID:29128638 D-glucose decreases expression EXP 6480464 Glucose results in decreased expression of MAP1LC3B protein CTD PMID:29128638 DDE decreases expression ISO RGD:1551009 6480464 Dichlorodiphenyl Dichloroethylene results in decreased expression of MAP1LC3B mRNA CTD PMID:32721735 Dehydroeburicoic acid multiple interactions ISO RGD:1350223 6480464 calpeptin inhibits the reaction [dehydroeburicoic acid affects the localization of MAP1LC3B protein] more ... CTD PMID:19848398 Dehydroeburicoic acid affects localization ISO RGD:1350223 6480464 dehydroeburicoic acid affects the localization of MAP1LC3B protein CTD PMID:19848398 deoxycholic acid multiple interactions ISO RGD:1350223 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA more ... CTD PMID:32152650 desferrioxamine B multiple interactions ISO RGD:1350223 6480464 Deferoxamine inhibits the reaction [di-n-propyldithiocarbamate results in increased expression of and results in increased lipidation of MAP1LC3B protein], Iron affects the reaction [Deferoxamine results in increased expression of MAP1LC3B protein] CTD PMID:25301941 , PMID:32687844 desferrioxamine B increases expression ISO RGD:1350223 6480464 Deferoxamine results in increased expression of MAP1LC3B protein CTD PMID:25301941 dexamethasone increases expression EXP 6480464 Dexamethasone results in increased expression of MAP1LC3B mRNA CTD PMID:20032058 dexamethasone multiple interactions ISO RGD:1350223 6480464 MAP1LC3B protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA], MAP1LC3B protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA] CTD PMID:23111315 dexamethasone multiple interactions EXP 6480464 Testosterone inhibits the reaction [Dexamethasone results in increased expression of MAP1LC3B mRNA] CTD PMID:20032058 dextran sulfate multiple interactions ISO RGD:1551009 6480464 2-methyl-2H-pyrazole-3-carboxylic acid 2-methyl-4-o-tolylazophenylamide inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of and results in increased lipidation of MAP1LC3B protein] more ... CTD PMID:31676321 diarsenic trioxide multiple interactions EXP 6480464 MAP1LC3B protein affects the reaction [Arsenic Trioxide results in decreased expression of SQSTM1 protein], MAP1LC3B protein affects the reaction [Arsenic Trioxide results in increased lipidation of MAP1LC3B protein] CTD PMID:29111283 diarsenic trioxide multiple interactions ISO RGD:1551009 6480464 Taurine inhibits the reaction [Arsenic Trioxide results in increased cleavage of MAP1LC3B protein], Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of MAP1LC3B protein] CTD PMID:30237538 , PMID:30677399 diarsenic trioxide increases lipidation ISO RGD:1551009 6480464 Arsenic Trioxide results in increased lipidation of MAP1LC3B protein CTD PMID:29111283 diarsenic trioxide increases cleavage ISO RGD:1350223 6480464 Arsenic Trioxide results in increased cleavage of MAP1LC3B protein CTD PMID:30677399 diarsenic trioxide multiple interactions ISO RGD:1350223 6480464 3-methyladenine inhibits the reaction [Arsenic Trioxide results in increased cleavage of MAP1LC3B protein] more ... CTD PMID:28978663 more ... diarsenic trioxide increases expression ISO RGD:1350223 6480464 Arsenic Trioxide results in increased expression of MAP1LC3B mRNA, Arsenic Trioxide results in increased expression of MAP1LC3B protein CTD PMID:29307831 more ... diarsenic trioxide increases cleavage ISO RGD:1551009 6480464 Arsenic Trioxide results in increased cleavage of MAP1LC3B protein CTD PMID:30677399 diarsenic trioxide increases lipidation EXP 6480464 Arsenic Trioxide results in increased lipidation of MAP1LC3B protein CTD PMID:29111283 diarsenic trioxide increases expression ISO RGD:1551009 6480464 Arsenic Trioxide results in increased expression of MAP1LC3B mRNA, Arsenic Trioxide results in increased expression of MAP1LC3B protein CTD PMID:30032600 more ... dibenzofuran affects localization ISO RGD:1350223 6480464 dibenzofuran affects the localization of MAP1LC3B protein CTD PMID:22173198 dibenzofuran increases expression ISO RGD:1350223 6480464 dibenzofuran results in increased expression of MAP1LC3B protein modified form CTD PMID:22173198 dibutyl phthalate increases expression ISO RGD:1551009 6480464 Dibutyl Phthalate results in increased expression of MAP1LC3B mRNA CTD PMID:21266533 dibutyl phthalate increases expression EXP 6480464 Dibutyl Phthalate results in increased expression of MAP1LC3B protein CTD PMID:30053495 dibutyl phthalate increases cleavage ISO RGD:1551009 6480464 Dibutyl Phthalate results in increased cleavage of MAP1LC3B protein CTD PMID:26804720 dibutyl phthalate multiple interactions ISO RGD:1551009 6480464 3-methyladenine inhibits the reaction [Dibutyl Phthalate results in increased cleavage of MAP1LC3B protein], 4-phenylbutyric acid inhibits the reaction [Dibutyl Phthalate results in increased cleavage of MAP1LC3B protein] CTD PMID:26804720 dibutyl phthalate increases cleavage EXP 6480464 Dibutyl Phthalate results in increased cleavage of MAP1LC3B protein CTD PMID:26804720 dibutyl phthalate multiple interactions EXP 6480464 3-methyladenine inhibits the reaction [Dibutyl Phthalate results in increased cleavage of MAP1LC3B protein], 4-phenylbutyric acid inhibits the reaction [Dibutyl Phthalate results in increased cleavage of MAP1LC3B protein] CTD PMID:26804720 dioxygen multiple interactions ISO RGD:1350223 6480464 Oxygen deficiency inhibits the reaction [Deoxyglucose results in increased prenylation of MAP1LC3B protein] CTD PMID:20593179 dioxygen increases expression ISO RGD:1551009 6480464 Oxygen deficiency results in increased expression of MAP1LC3B mRNA CTD PMID:23624791 diquat multiple interactions ISO RGD:1551009 6480464 [Diquat co-treated with procyanidin B2] results in increased expression of MAP1LC3B mRNA CTD PMID:27057282 disodium selenite multiple interactions EXP 6480464 Sodium Selenite inhibits the reaction [citreoviridin results in increased expression of MAP1LC3B protein modified form] CTD PMID:31419397 disodium selenite multiple interactions ISO RGD:1551009 6480464 Sodium Selenite inhibits the reaction [citreoviridin results in increased expression of MAP1LC3B protein modified form] CTD PMID:31419397 disodium selenite multiple interactions ISO RGD:1350223 6480464 [Sodium Selenite co-treated with 1 more ... CTD PMID:28757135 disulfiram multiple interactions ISO RGD:1350223 6480464 [Disulfiram binds to Copper] which results in decreased expression of MAP1LC3B mRNA CTD PMID:24690739 dorsomorphin multiple interactions ISO RGD:1350223 6480464 dorsomorphin inhibits the reaction [Artesunate results in increased lipidation of MAP1LC3B protein], dorsomorphin inhibits the reaction [Resveratrol affects the metabolism of MAP1LC3B protein] CTD PMID:23680031 , PMID:33002460 doxorubicin multiple interactions EXP 6480464 [Doxorubicin co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein more ... CTD PMID:32525084 doxorubicin increases expression ISO RGD:1350223 6480464 Doxorubicin results in increased expression of MAP1LC3B mRNA CTD PMID:29803840 doxorubicin increases lipidation ISO RGD:1350223 6480464 Doxorubicin results in increased lipidation of MAP1LC3B protein CTD PMID:26969377 doxorubicin multiple interactions ISO RGD:1350223 6480464 [Doxorubicin co-treated with resveratrol] results in increased lipidation of MAP1LC3B protein CTD PMID:26969377 entinostat increases expression ISO RGD:1350223 6480464 entinostat results in increased expression of MAP1LC3B protein modified form CTD PMID:20962572 erlotinib hydrochloride multiple interactions ISO RGD:1350223 6480464 Erlotinib Hydrochloride promotes the reaction [betulinic acid results in increased expression of MAP1LC3B protein modified form] CTD PMID:30136359 ethanol increases lipidation ISO RGD:1551009 6480464 Ethanol results in increased lipidation of MAP1LC3B protein CTD PMID:24492484 ethanol increases expression ISO RGD:1551009 6480464 Ethanol results in increased expression of MAP1LC3B mRNA, Ethanol results in increased expression of MAP1LC3B protein CTD PMID:24095927 more ... ethanol multiple interactions ISO RGD:1350223 6480464 Chloroquine promotes the reaction [Ethanol results in increased expression of MAP1LC3B protein] CTD PMID:24095927 ethanol increases expression ISO RGD:1350223 6480464 Ethanol results in increased expression of MAP1LC3B mRNA more ... CTD PMID:24095927 , PMID:29524503 ethanol multiple interactions ISO RGD:1551009 6480464 [Ethanol co-treated with Chloroquine] results in increased lipidation of MAP1LC3B protein more ... CTD PMID:24095927 more ... ethyl methanesulfonate increases expression ISO RGD:1350223 6480464 Ethyl Methanesulfonate results in increased expression of MAP1LC3B mRNA CTD PMID:23649840 ferric oxide increases expression ISO RGD:1551009 6480464 ferric oxide analog results in increased expression of MAP1LC3B protein CTD PMID:24068039 finasteride increases expression EXP 6480464 Finasteride results in increased expression of MAP1LC3B mRNA CTD PMID:24136188 flavokawain B multiple interactions ISO RGD:1350223 6480464 3-methyladenine inhibits the reaction [flavokawain B results in increased expression of MAP1LC3B protein modified form] more ... CTD PMID:30025493 flavokawain B increases expression ISO RGD:1350223 6480464 flavokawain B results in increased expression of MAP1LC3B protein modified form CTD PMID:30025493 flavonoids decreases expression EXP 6480464 Flavonoids results in decreased expression of MAP1LC3B mRNA CTD PMID:18035473 flutamide increases expression EXP 6480464 Flutamide results in increased expression of MAP1LC3B mRNA CTD PMID:24136188 folic acid multiple interactions ISO RGD:1551009 6480464 [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of MAP1LC3B mRNA CTD PMID:22206623 folic acid affects expression ISO RGD:1551009 6480464 Folic Acid affects the expression of MAP1LC3B mRNA CTD PMID:25629700 fomepizole multiple interactions ISO RGD:1551009 6480464 fomepizole inhibits the reaction [Ethanol results in increased lipidation of MAP1LC3B protein] CTD PMID:24492484 formaldehyde increases expression ISO RGD:1350223 6480464 Formaldehyde results in increased expression of MAP1LC3B mRNA CTD PMID:23649840 formaldehyde increases expression EXP 6480464 Formaldehyde results in increased expression of MAP1LC3B mRNA CTD PMID:24142868 gamma-hexachlorocyclohexane increases expression EXP 6480464 Hexachlorocyclohexane results in increased expression of MAP1LC3B mRNA CTD PMID:17785943 gingerol multiple interactions ISO RGD:1350223 6480464 [gingerol co-treated with Hydrogen Peroxide] results in increased expression of MAP1LC3B protein modified form CTD PMID:27451028 ginsenoside Rg2 multiple interactions ISO RGD:1350223 6480464 bafilomycin A1 promotes the reaction [ginsenoside Rg2 results in increased expression of MAP1LC3B protein modified form] CTD PMID:27305347 ginsenoside Rg2 increases expression ISO RGD:1350223 6480464 ginsenoside Rg2 results in increased expression of MAP1LC3B protein modified form CTD PMID:27305347 glafenine increases expression EXP 6480464 Glafenine results in increased expression of MAP1LC3B mRNA CTD PMID:24136188 glucose multiple interactions EXP 6480464 3-methyladenine inhibits the reaction [N-1 more ... CTD PMID:29128638 glucose decreases expression EXP 6480464 Glucose results in decreased expression of MAP1LC3B protein CTD PMID:29128638 glutathione multiple interactions ISO RGD:1350223 6480464 Glutathione inhibits the reaction [Apigenin results in increased expression of MAP1LC3B protein modified form] CTD PMID:29247770 glutathione increases expression EXP 6480464 Glutathione deficiency results in increased expression of MAP1LC3B mRNA CTD PMID:15345336 glycerol 2-phosphate multiple interactions ISO RGD:1350223 6480464 MAP1LC3B protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA], MAP1LC3B protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA] CTD PMID:23111315 glycochenodeoxycholic acid decreases expression ISO RGD:1350223 6480464 Glycochenodeoxycholic Acid results in decreased expression of MAP1LC3B mRNA CTD PMID:32439580 glycochenodeoxycholic acid multiple interactions ISO RGD:1350223 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA more ... CTD PMID:32152650 , PMID:32439580 glycocholic acid multiple interactions ISO RGD:1350223 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA more ... CTD PMID:32152650 glycodeoxycholic acid multiple interactions ISO RGD:1350223 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA more ... CTD PMID:32152650 glycyrrhizinic acid multiple interactions EXP 6480464 [Glycyrrhizic Acid co-treated with bafilomycin A1] results in increased lipidation of MAP1LC3B protein more ... CTD PMID:32525084 hexadecanoic acid affects localization ISO RGD:1551009 6480464 Palmitic Acid affects the localization of MAP1LC3B protein CTD PMID:30208301 hexadecanoic acid increases expression EXP 6480464 Palmitic Acid results in increased expression of MAP1LC3B protein modified form CTD PMID:32278738 hexadecanoic acid multiple interactions EXP 6480464 C1QTNF9 protein promotes the reaction [Palmitic Acid results in increased expression of MAP1LC3B protein modified form] CTD PMID:32278738 hexadecanoic acid multiple interactions ISO RGD:1350223 6480464 [Palmitic Acid co-treated with Oleic Acid] affects the expression of MAP1LC3B mRNA CTD PMID:30547786 hyaluronic acid multiple interactions EXP 6480464 FG-4592 promotes the reaction [Hyaluronic Acid results in increased cleavage of MAP1LC3B protein] CTD PMID:27082295 hyaluronic acid increases cleavage EXP 6480464 Hyaluronic Acid results in increased cleavage of MAP1LC3B protein CTD PMID:27082295 hydrogen peroxide affects expression ISO RGD:1350223 6480464 Hydrogen Peroxide affects the expression of MAP1LC3B mRNA CTD PMID:20044591 hydrogen peroxide multiple interactions ISO RGD:1551009 6480464 [Hydrogen Peroxide co-treated with procyanidin B2] results in increased expression of MAP1LC3B mRNA CTD PMID:27057282 hydrogen peroxide multiple interactions ISO RGD:1350223 6480464 3-methyladenine inhibits the reaction [Hydrogen Peroxide results in increased expression of MAP1LC3B mRNA] more ... CTD PMID:27451028 , PMID:32043704 hydrogen peroxide decreases expression ISO RGD:1350223 6480464 Hydrogen Peroxide results in decreased expression of MAP1LC3B protein alternative form CTD PMID:23726866 hydrogen peroxide increases expression ISO RGD:1350223 6480464 Hydrogen Peroxide results in increased expression of MAP1LC3B mRNA more ... CTD PMID:23726866 , PMID:32043704 indoxyl sulfate multiple interactions ISO RGD:1551009 6480464 Acetylcysteine inhibits the reaction [Indican results in increased expression of MAP1LC3B protein] CTD PMID:30849338 indoxyl sulfate increases expression ISO RGD:1551009 6480464 Indican results in increased expression of MAP1LC3B protein CTD PMID:30849338 iron atom multiple interactions ISO RGD:1350223 6480464 Iron affects the reaction [Deferoxamine results in increased expression of MAP1LC3B protein] more ... CTD PMID:25301941 iron(0) multiple interactions ISO RGD:1350223 6480464 Iron affects the reaction [Deferoxamine results in increased expression of MAP1LC3B protein] more ... CTD PMID:25301941 juglone multiple interactions ISO RGD:1350223 6480464 juglone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MAP1LC3B protein] CTD PMID:20479004 kainic acid multiple interactions EXP 6480464 NADP inhibits the reaction [Kainic Acid results in increased expression of MAP1LC3B protein modified form] CTD PMID:32057834 kainic acid increases expression EXP 6480464 Kainic Acid results in increased expression of MAP1LC3B protein modified form CTD PMID:32057834 L-ascorbic acid 2-phosphate multiple interactions ISO RGD:1350223 6480464 MAP1LC3B protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA], MAP1LC3B protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA] CTD PMID:23111315 L-leucine multiple interactions ISO RGD:1551009 6480464 Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of and results in increased lipidation of MAP1LC3B protein] CTD PMID:31676321 lead(0) affects expression ISO RGD:1350223 6480464 Lead affects the expression of MAP1LC3B mRNA CTD PMID:28903495 lead(2+) affects expression ISO RGD:1350223 6480464 Lead affects the expression of MAP1LC3B mRNA CTD PMID:28903495 leflunomide increases expression EXP 6480464 leflunomide results in increased expression of MAP1LC3B mRNA CTD PMID:24136188 leflunomide increases expression ISO RGD:1350223 6480464 leflunomide results in increased expression of MAP1LC3B mRNA CTD PMID:28988120 luteolin multiple interactions ISO RGD:1350223 6480464 Luteolin results in increased expression of and results in increased lipidation of MAP1LC3B protein, PD 0325901 inhibits the reaction [Luteolin results in increased expression of and results in increased lipidation of MAP1LC3B protein] CTD PMID:32268164 LY294002 multiple interactions EXP 6480464 2-4-morpholinyl-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [saikosaponin D results in decreased cleavage of MAP1LC3B protein], 2-4-morpholinyl-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [saikosaponin D results in increased expression of MAP1LC3B protein] CTD PMID:30611790 LY294002 increases cleavage EXP 6480464 2-4-morpholinyl-8-phenyl-4H-1-benzopyran-4-one results in increased cleavage of MAP1LC3B protein CTD PMID:30611790 mannose multiple interactions ISO RGD:1350223 6480464 Mannose inhibits the reaction [Deoxyglucose results in increased prenylation of MAP1LC3B protein] CTD PMID:20593179 menadione multiple interactions ISO RGD:1350223 6480464 [Metyrapone co-treated with Vitamin K 3] results in increased expression of MAP1LC3B protein, [S 3483 co-treated with Vitamin K 3] results in increased expression of MAP1LC3B protein CTD PMID:19819344 metformin multiple interactions ISO RGD:1350223 6480464 [Simvastatin co-treated with Metformin] results in increased expression of MAP1LC3B protein modified form, Chloroquine promotes the reaction [[Simvastatin co-treated with Metformin] results in increased expression of MAP1LC3B protein modified form] CTD PMID:25412314 methotrexate increases expression ISO RGD:1350223 6480464 Methotrexate results in increased expression of MAP1LC3B mRNA CTD PMID:21678067 methyl methanesulfonate increases expression ISO RGD:1350223 6480464 Methyl Methanesulfonate results in increased expression of MAP1LC3B mRNA CTD PMID:23649840 methylisothiazolinone multiple interactions ISO RGD:1350223 6480464 2-methyl-4-isothiazolin-3-one results in increased expression of and results in increased cleavage of MAP1LC3B protein CTD PMID:29110394 methylisothiazolinone increases expression ISO RGD:1350223 6480464 2-methyl-4-isothiazolin-3-one results in increased expression of MAP1LC3B protein CTD PMID:31629900 methylmercury chloride increases expression ISO RGD:1551009 6480464 methylmercuric chloride results in increased expression of MAP1LC3B protein modified form CTD PMID:27667695 methylmercury chloride increases expression ISO RGD:1350223 6480464 methylmercuric chloride results in increased expression of MAP1LC3B mRNA, methylmercuric chloride results in increased expression of MAP1LC3B protein modified form CTD PMID:27667695 , PMID:28001369 methylmercury chloride multiple interactions ISO RGD:1551009 6480464 ATG5 promotes the reaction [methylmercuric chloride results in increased cleavage of MAP1LC3B protein], U 0126 inhibits the reaction [methylmercuric chloride results in increased expression of MAP1LC3B protein modified form] CTD PMID:27667695 methylmercury chloride increases cleavage ISO RGD:1551009 6480464 methylmercuric chloride results in increased cleavage of MAP1LC3B protein CTD PMID:27667695 methylphenidate decreases expression ISO RGD:1551009 6480464 Methylphenidate results in decreased expression of MAP1LC3B mRNA CTD PMID:22470460 metyrapone multiple interactions ISO RGD:1350223 6480464 [Metyrapone co-treated with Vitamin K 3] results in increased expression of MAP1LC3B protein CTD PMID:19819344 myriocin multiple interactions ISO RGD:1350223 6480464 thermozymocidin inhibits the reaction [Dronabinol results in increased expression of and affects the localization of and affects the lipidation of MAP1LC3B protein] CTD PMID:27635674 N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide multiple interactions EXP 6480464 3-methyladenine inhibits the reaction [N-1 more ... CTD PMID:29128638 N-acetyl-L-cysteine multiple interactions ISO RGD:1350223 6480464 Acetylcysteine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased metabolism of MAP1LC3B protein] more ... CTD PMID:20543569 more ... N-acetyl-L-cysteine multiple interactions ISO RGD:1551009 6480464 Acetylcysteine inhibits the reaction [cupric chloride results in increased expression of MAP1LC3B protein modified form], Acetylcysteine inhibits the reaction [Indican results in increased expression of MAP1LC3B protein] CTD PMID:30849338 , PMID:32512069 N-acetyl-L-cysteine multiple interactions EXP 6480464 Acetylcysteine inhibits the reaction [cadmium acetate affects the localization of [LAMP1 protein co-treated with MAP1LC3B protein]] more ... CTD PMID:27832966 , PMID:28347754 N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal increases expression ISO RGD:1350223 6480464 benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MAP1LC3B protein modified form CTD PMID:26409479 N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal multiple interactions ISO RGD:1350223 6480464 MAP1LC3B protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of NFKBIA protein] CTD PMID:24085292 NADP zwitterion multiple interactions EXP 6480464 NADP inhibits the reaction [Kainic Acid results in increased expression of MAP1LC3B protein modified form] CTD PMID:32057834 NADP(+) multiple interactions EXP 6480464 NADP inhibits the reaction [Kainic Acid results in increased expression of MAP1LC3B protein modified form] CTD PMID:32057834 Naftopidil affects expression ISO RGD:1350223 6480464 naftopidil affects the expression of MAP1LC3B protein CTD PMID:29374705 nefazodone increases expression EXP 6480464 nefazodone results in increased expression of MAP1LC3B mRNA CTD PMID:24136188 nefazodone multiple interactions ISO RGD:1350223 6480464 [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA CTD PMID:32152650 nefazodone increases expression ISO RGD:1350223 6480464 nefazodone results in increased expression of MAP1LC3B mRNA CTD PMID:32152650 nelfinavir increases expression ISO RGD:1350223 6480464 Nelfinavir results in increased expression of MAP1LC3B protein CTD PMID:20594311 nelfinavir multiple interactions ISO RGD:1350223 6480464 Tamoxifen promotes the reaction [Nelfinavir results in increased expression of MAP1LC3B protein] CTD PMID:20594311 niclosamide increases expression ISO RGD:1350223 6480464 Niclosamide results in increased expression of MAP1LC3B protein modified form CTD PMID:30258081 nicotinamide multiple interactions ISO RGD:1350223 6480464 Niacinamide inhibits the reaction [[TNF protein co-treated with resveratrol] results in increased expression of MAP1LC3B protein alternative form] CTD PMID:24145604 nimesulide increases expression EXP 6480464 nimesulide results in increased expression of MAP1LC3B mRNA CTD PMID:24136188 Nonylphenol increases cleavage EXP 6480464 nonylphenol results in increased cleavage of MAP1LC3B protein CTD PMID:27832966 Nonylphenol affects expression EXP 6480464 nonylphenol affects the expression of MAP1LC3B protein CTD PMID:27832966 Nonylphenol multiple interactions EXP 6480464 Acetylcysteine inhibits the reaction [nonylphenol results in increased expression of MAP1LC3B protein] CTD PMID:27832966 obeticholic acid multiple interactions ISO RGD:1551009 6480464 obeticholic acid inhibits the reaction [Dietary Fats results in decreased expression of MAP1LC3B protein] CTD PMID:26655953 oleanolic acid multiple interactions ISO RGD:1350223 6480464 Cisplatin promotes the reaction [Oleanolic Acid results in increased expression of MAP1LC3B protein], Oleanolic Acid promotes the reaction [Cisplatin results in increased expression of MAP1LC3B protein] CTD PMID:31306688 oleanolic acid increases expression ISO RGD:1350223 6480464 Oleanolic Acid results in increased expression of MAP1LC3B protein CTD PMID:31306688 oleanolic acid multiple interactions ISO RGD:1551009 6480464 Oleanolic Acid inhibits the reaction [Cisplatin results in increased expression of MAP1LC3B protein] CTD PMID:31306688 oleic acid multiple interactions ISO RGD:1350223 6480464 [Palmitic Acid co-treated with Oleic Acid] affects the expression of MAP1LC3B mRNA CTD PMID:30547786 oxidopamine increases expression EXP 6480464 Oxidopamine results in increased expression of MAP1LC3B protein modified form CTD PMID:28802652 paclitaxel increases expression ISO RGD:1350223 6480464 Paclitaxel results in increased expression of MAP1LC3B mRNA, Paclitaxel results in increased expression of MAP1LC3B protein CTD PMID:19815708 paracetamol increases expression ISO RGD:1350223 6480464 Acetaminophen results in increased expression of MAP1LC3B mRNA CTD PMID:21420995 , PMID:29067470 paracetamol increases expression EXP 6480464 Acetaminophen results in increased expression of MAP1LC3B protein CTD PMID:28682524 paracetamol multiple interactions EXP 6480464 chrysin inhibits the reaction [Acetaminophen results in increased expression of MAP1LC3B protein] CTD PMID:28682524 paraquat multiple interactions ISO RGD:1551009 6480464 bafilomycin A promotes the reaction [Paraquat results in increased expression of MAP1LC3B protein] more ... CTD PMID:27246695 paraquat increases expression ISO RGD:1350223 6480464 Paraquat results in increased expression of MAP1LC3B mRNA CTD PMID:27220436 paraquat multiple interactions ISO RGD:1350223 6480464 Paraquat inhibits the reaction [Chloroquine results in increased expression of MAP1LC3B protein modified form] CTD PMID:26409479 paraquat increases expression ISO RGD:1551009 6480464 Paraquat results in increased expression of MAP1LC3B protein CTD PMID:25092649 , PMID:27246695 PD 0325901 multiple interactions ISO RGD:1350223 6480464 PD 0325901 inhibits the reaction [Luteolin results in increased expression of and results in increased lipidation of MAP1LC3B protein] CTD PMID:32268164 pepstatin A multiple interactions ISO RGD:1350223 6480464 [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form] more ... CTD PMID:21184746 , PMID:27635674 pepstatin A multiple interactions ISO RGD:1551009 6480464 [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form] more ... CTD PMID:27635674 perfluorooctanoic acid multiple interactions ISO RGD:1350223 6480464 ATG5 protein promotes the reaction [perfluorooctanoic acid results in increased expression of MAP1LC3B protein modified form] CTD PMID:26879310 perfluorooctanoic acid increases expression ISO RGD:1551009 6480464 perfluorooctanoic acid results in increased expression of MAP1LC3B mRNA, perfluorooctanoic acid results in increased expression of MAP1LC3B protein modified form CTD PMID:26879310 perfluorooctanoic acid increases expression ISO RGD:1350223 6480464 perfluorooctanoic acid results in increased expression of MAP1LC3B protein modified form CTD PMID:26879310 phenobarbital increases expression EXP 6480464 Phenobarbital results in increased expression of MAP1LC3B mRNA CTD PMID:19162173 phenobarbital affects expression ISO RGD:1350223 6480464 Phenobarbital affects the expression of MAP1LC3B mRNA CTD PMID:19159669 phorbol 13-acetate 12-myristate multiple interactions ISO RGD:1350223 6480464 2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MAP1LC3B protein] more ... CTD PMID:20479004 phorbol 13-acetate 12-myristate increases expression ISO RGD:1350223 6480464 Tetradecanoylphorbol Acetate results in increased expression of MAP1LC3B protein CTD PMID:20479004 phosphatidylethanolamine multiple interactions ISO RGD:1350223 6480464 calpeptin inhibits the reaction [dehydroeburicoic acid promotes the reaction [MAP1LC3B protein binds to phosphatidylethanolamine]], dehydroeburicoic acid promotes the reaction [MAP1LC3B protein binds to phosphatidylethanolamine] CTD PMID:19848398 pirinixic acid multiple interactions ISO RGD:1551009 6480464 PPARA protein affects the reaction [pirinixic acid results in increased expression of MAP1LC3B mRNA] CTD PMID:21318169 pirinixic acid increases expression ISO RGD:1551009 6480464 pirinixic acid results in increased expression of MAP1LC3B mRNA CTD PMID:18301758 more ... platycodin D increases expression ISO RGD:1350223 6480464 platycodin D results in increased expression of MAP1LC3B mRNA, platycodin D results in increased expression of MAP1LC3B protein CTD PMID:26078792 potassium chromate multiple interactions ISO RGD:1350223 6480464 [potassium chromateVI co-treated with epigallocatechin gallate] results in increased expression of MAP1LC3B mRNA CTD PMID:22079256 potassium chromate increases expression ISO RGD:1350223 6480464 potassium chromateVI results in increased expression of MAP1LC3B mRNA CTD PMID:22079256 , PMID:22714537 pregnenolone 16alpha-carbonitrile increases expression ISO RGD:1551009 6480464 Pregnenolone Carbonitrile results in increased expression of MAP1LC3B mRNA CTD PMID:28903501 procyanidin B2 multiple interactions ISO RGD:1551009 6480464 [Diquat co-treated with procyanidin B2] results in increased expression of MAP1LC3B mRNA, [Hydrogen Peroxide co-treated with procyanidin B2] results in increased expression of MAP1LC3B mRNA CTD PMID:27057282 quercetin increases expression ISO RGD:1350223 6480464 Quercetin results in increased expression of MAP1LC3B mRNA, Quercetin results in increased expression of MAP1LC3B protein CTD PMID:21632981 , PMID:28251795 quercetin increases cleavage ISO RGD:1350223 6480464 Quercetin results in increased cleavage of MAP1LC3B protein CTD PMID:28251795 quercetin multiple interactions ISO RGD:1350223 6480464 3-methyladenine inhibits the reaction [Quercetin results in increased cleavage of MAP1LC3B protein], benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane inhibits the reaction [Quercetin results in increased cleavage of MAP1LC3B protein] CTD PMID:28251795 quetiapine fumarate decreases metabolic processing ISO RGD:1551009 6480464 Quetiapine Fumarate results in decreased metabolism of MAP1LC3B protein CTD PMID:31220554 resveratrol affects metabolic processing ISO RGD:1350223 6480464 resveratrol affects the metabolism of MAP1LC3B protein CTD PMID:23680031 resveratrol increases lipidation EXP 6480464 Resveratrol results in increased lipidation of MAP1LC3B protein CTD PMID:32619457 resveratrol increases lipidation ISO RGD:1350223 6480464 resveratrol results in increased lipidation of MAP1LC3B protein CTD PMID:26969377 resveratrol multiple interactions EXP 6480464 [Benzoapyrene co-treated with Resveratrol] promotes the reaction [MAP1LC3B protein binds to TOMM20 protein] more ... CTD PMID:32619457 resveratrol increases expression ISO RGD:1551009 6480464 resveratrol results in increased expression of MAP1LC3B mRNA CTD PMID:24095927 resveratrol multiple interactions ISO RGD:1551009 6480464 resveratrol promotes the reaction [Ethanol results in increased expression of MAP1LC3B mRNA] CTD PMID:24095927 resveratrol multiple interactions ISO RGD:1350223 6480464 3-methyladenine inhibits the reaction [[TNF protein co-treated with Resveratrol] results in increased expression of MAP1LC3B protein alternative form] more ... CTD PMID:23680031 more ... resveratrol increases expression ISO RGD:1350223 6480464 resveratrol results in increased expression of MAP1LC3B mRNA, resveratrol results in increased expression of MAP1LC3B protein alternative form CTD PMID:23750556 , PMID:24145604 rifampicin decreases metabolic processing ISO RGD:1350223 6480464 Rifampin results in decreased metabolism of MAP1LC3B protein CTD PMID:29908302 rifampicin increases lipidation ISO RGD:1350223 6480464 Rifampin results in increased lipidation of MAP1LC3B protein CTD PMID:31648047 rifampicin multiple interactions ISO RGD:1350223 6480464 ATP6V0D1 protein affects the reaction [Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]] more ... CTD PMID:31648047 rimonabant multiple interactions ISO RGD:1551009 6480464 Rimonabant results in increased expression of and results in increased lipidation of MAP1LC3B protein CTD PMID:31570772 rotenone decreases expression ISO RGD:1551009 6480464 Rotenone results in decreased expression of MAP1LC3B mRNA CTD PMID:23186747 rotenone multiple interactions ISO RGD:1350223 6480464 [Rotenone co-treated with bafilomycin B1] results in increased lipidation of and results in increased cleavage of MAP1LC3B protein more ... CTD PMID:30673822 , PMID:31648047 rotenone increases lipidation ISO RGD:1350223 6480464 Rotenone results in increased lipidation of MAP1LC3B protein CTD PMID:31648047 rotenone increases expression EXP 6480464 Rotenone results in increased expression of MAP1LC3B mRNA CTD PMID:28374803 rotenone multiple interactions ISO RGD:1551009 6480464 wortmannin inhibits the reaction [Rotenone results in increased expression of MAP1LC3B protein] CTD PMID:26847702 rotenone increases expression ISO RGD:1551009 6480464 Rotenone results in increased expression of MAP1LC3B protein CTD PMID:26847702 serpentine asbestos increases expression ISO RGD:1350223 6480464 Asbestos, Serpentine results in increased expression of MAP1LC3B mRNA CTD PMID:24735948 silicon dioxide increases expression ISO RGD:1350223 6480464 Silicon Dioxide analog results in increased expression of MAP1LC3B mRNA, Silicon Dioxide analog results in increased expression of MAP1LC3B protein CTD PMID:23806026 , PMID:25895662 silicon dioxide increases expression ISO RGD:1551009 6480464 Silicon Dioxide analog results in increased expression of MAP1LC3B protein alternative form, Silicon Dioxide results in increased expression of MAP1LC3B mRNA CTD PMID:19073995 , PMID:28161448 silver atom increases expression ISO RGD:1350223 6480464 Silver results in increased expression of MAP1LC3B mRNA, Silver results in increased expression of MAP1LC3B protein modified form CTD PMID:26014281 , PMID:28987793 silver(0) increases expression ISO RGD:1350223 6480464 Silver results in increased expression of MAP1LC3B mRNA, Silver results in increased expression of MAP1LC3B protein modified form CTD PMID:26014281 , PMID:28987793 simvastatin increases expression ISO RGD:1551009 6480464 Simvastatin results in increased expression of MAP1LC3B protein CTD PMID:23817226 simvastatin multiple interactions ISO RGD:1350223 6480464 [Simvastatin co-treated with Metformin] results in increased expression of MAP1LC3B protein modified form, Chloroquine promotes the reaction [[Simvastatin co-treated with Metformin] results in increased expression of MAP1LC3B protein modified form] CTD PMID:25412314 sirolimus increases expression ISO RGD:1350223 6480464 Sirolimus results in increased expression of MAP1LC3B mRNA more ... CTD PMID:19815708 more ... sirolimus increases lipidation ISO RGD:1551009 6480464 Sirolimus results in increased lipidation of MAP1LC3B protein CTD PMID:29793971 sirolimus multiple interactions ISO RGD:1350223 6480464 Sirolimus promotes the reaction [2 more ... CTD PMID:29518472 more ... sirolimus multiple interactions ISO RGD:1551009 6480464 CD38 gene mutant form promotes the reaction [Sirolimus results in increased expression of MAP1LC3B protein] more ... CTD PMID:24445604 more ... sirolimus affects metabolic processing ISO RGD:1350223 6480464 Sirolimus affects the metabolism of MAP1LC3B protein CTD PMID:23680031 sirolimus increases expression EXP 6480464 Sirolimus results in increased expression of MAP1LC3B mRNA, Sirolimus results in increased expression of MAP1LC3B protein modified form CTD PMID:18640276 , PMID:30611790 sirolimus multiple interactions EXP 6480464 3-methyladenine inhibits the reaction [Sirolimus results in increased expression of MAP1LC3B protein modified form] more ... CTD PMID:18640276 more ... sirolimus affects localization EXP 6480464 Sirolimus affects the localization of MAP1LC3B protein CTD PMID:18640276 sirolimus increases expression ISO RGD:1551009 6480464 Sirolimus results in increased expression of MAP1LC3B mRNA more ... CTD PMID:21681844 more ... sodium arsenate multiple interactions ISO RGD:1350223 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of and results in increased lipidation of MAP1LC3B protein CTD PMID:32525701 sodium arsenite increases expression ISO RGD:1350223 6480464 sodium arsenite results in increased expression of MAP1LC3B protein CTD PMID:19577553 more ... sodium arsenite multiple interactions EXP 6480464 [[sodium arsenite results in increased abundance of Arsenic] co-treated with [Sodium Fluoride results in increased abundance of Fluorides]] results in increased expression of MAP1LC3B mRNA, [sodium arsenite results in increased abundance of Arsenic] which results in increased expression of MAP1LC3B mRNA CTD PMID:31844926 sodium arsenite decreases expression ISO RGD:1350223 6480464 sodium arsenite results in decreased expression of MAP1LC3B mRNA CTD PMID:28595984 sodium arsenite increases expression EXP 6480464 sodium arsenite results in increased expression of MAP1LC3B protein CTD PMID:26432159 sodium arsenite decreases expression EXP 6480464 sodium arsenite results in decreased expression of MAP1LC3B mRNA CTD PMID:19072884 sodium arsenite increases expression ISO RGD:1551009 6480464 sodium arsenite results in increased expression of MAP1LC3B protein CTD PMID:27413109 sodium arsenite multiple interactions ISO RGD:1350223 6480464 Decitabine inhibits the reaction [sodium arsenite results in increased expression of MAP1LC3B protein] more ... CTD PMID:19577553 , PMID:27107786 sodium fluoride increases expression ISO RGD:1551009 6480464 Sodium Fluoride results in increased expression of MAP1LC3B mRNA CTD PMID:29505816 , PMID:30225638 sodium fluoride multiple interactions EXP 6480464 [[sodium arsenite results in increased abundance of Arsenic] co-treated with [Sodium Fluoride results in increased abundance of Fluorides]] results in increased expression of MAP1LC3B mRNA, [Sodium Fluoride results in increased abundance of Fluorides] which results in increased expression of MAP1LC3B mRNA CTD PMID:31844926 sodium fluoride multiple interactions ISO RGD:1551009 6480464 TGFB1 protein promotes the reaction [Sodium Fluoride results in increased expression of MAP1LC3B mRNA] CTD PMID:29505816 Soman increases expression EXP 6480464 Soman results in increased expression of MAP1LC3B mRNA CTD PMID:19281266 spironolactone increases expression EXP 6480464 Spironolactone results in increased expression of MAP1LC3B protein CTD PMID:30734886 sulforaphane increases expression ISO RGD:1350223 6480464 sulforaphane results in increased expression of MAP1LC3B mRNA CTD PMID:32111854 sulfur dioxide multiple interactions EXP 6480464 Sulfur Dioxide inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased lipidation of MAP1LC3B protein] CTD PMID:30503585 T-2 toxin increases expression EXP 6480464 T-2 Toxin results in increased expression of MAP1LC3B mRNA CTD PMID:29413859 T-2 toxin multiple interactions EXP 6480464 T-2 Toxin results in increased expression of and results in increased cleavage of MAP1LC3B protein CTD PMID:29413859 tamoxifen decreases response to substance ISO RGD:1350223 6480464 MAP1LC3B protein results in decreased susceptibility to Tamoxifen CTD PMID:20479004 tamoxifen increases expression ISO RGD:1350223 6480464 Tamoxifen results in increased expression of MAP1LC3B protein CTD PMID:25301941 tamoxifen affects expression ISO RGD:1551009 6480464 Tamoxifen affects the expression of MAP1LC3B mRNA CTD PMID:17555576 tamoxifen multiple interactions ISO RGD:1350223 6480464 Tamoxifen promotes the reaction [Nelfinavir results in increased expression of MAP1LC3B protein] CTD PMID:20594311 taurine multiple interactions ISO RGD:1350223 6480464 Taurine inhibits the reaction [Arsenic Trioxide results in increased cleavage of MAP1LC3B protein], Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of MAP1LC3B protein] CTD PMID:30237538 , PMID:30677399 taurine multiple interactions ISO RGD:1551009 6480464 Taurine inhibits the reaction [Arsenic Trioxide results in increased cleavage of MAP1LC3B protein], Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of MAP1LC3B protein] CTD PMID:30237538 , PMID:30677399 taurocholic acid increases expression ISO RGD:1551009 6480464 Taurocholic Acid results in increased expression of MAP1LC3B protein CTD PMID:24189133 temozolomide increases expression ISO RGD:1350223 6480464 temozolomide results in increased expression of MAP1LC3B protein CTD PMID:19567134 temozolomide multiple interactions ISO RGD:1350223 6480464 Thalidomide promotes the reaction [temozolomide results in increased expression of MAP1LC3B protein] CTD PMID:19567134 tert-butyl hydroperoxide increases expression ISO RGD:1350223 6480464 tert-Butylhydroperoxide results in increased expression of MAP1LC3B mRNA CTD PMID:15336504 testosterone multiple interactions EXP 6480464 Testosterone inhibits the reaction [Dexamethasone results in increased expression of MAP1LC3B mRNA] CTD PMID:20032058 tetrachloromethane affects expression ISO RGD:1551009 6480464 Carbon Tetrachloride affects the expression of MAP1LC3B mRNA CTD PMID:17484886 thalidomide multiple interactions ISO RGD:1350223 6480464 Thalidomide promotes the reaction [temozolomide results in increased expression of MAP1LC3B protein] CTD PMID:19567134 thapsigargin multiple interactions EXP 6480464 Thapsigargin affects the localization of [LAMP1 protein co-treated with MAP1LC3B protein] more ... CTD PMID:28347754 thapsigargin multiple interactions ISO RGD:1350223 6480464 Thapsigargin promotes the reaction [Cadmium Chloride results in increased expression of MAP1LC3B protein modified form] CTD PMID:25639782 thiamine(1+) chloride multiple interactions EXP 6480464 Thiamine inhibits the reaction [citreoviridin results in increased expression of MAP1LC3B protein modified form] CTD PMID:31419397 thiamine(1+) chloride multiple interactions ISO RGD:1551009 6480464 Thiamine inhibits the reaction [citreoviridin results in increased expression of MAP1LC3B protein modified form] CTD PMID:31419397 titanium dioxide increases lipidation ISO RGD:1350223 6480464 titanium dioxide results in increased lipidation of MAP1LC3B protein CTD PMID:31927068 titanium dioxide increases expression ISO RGD:1551009 6480464 titanium dioxide analog results in increased expression of MAP1LC3B protein CTD PMID:25111187 trametinib multiple interactions ISO RGD:1350223 6480464 trametinib affects the expression of and affects the lipidation of MAP1LC3B protein CTD PMID:30339727 trichostatin A affects localization ISO RGD:1350223 6480464 trichostatin A affects the localization of MAP1LC3B protein modified form CTD PMID:20543569 trichostatin A multiple interactions ISO RGD:1551009 6480464 ATG7 gene mutant form inhibits the reaction [trichostatin A promotes the reaction [Cisplatin results in increased expression of MAP1LC3B protein modified form]] more ... CTD PMID:29476062 trichostatin A increases expression EXP 6480464 trichostatin A results in increased expression of MAP1LC3B protein modified form CTD PMID:29476062 trichostatin A multiple interactions EXP 6480464 Chloroquine promotes the reaction [trichostatin A results in increased expression of MAP1LC3B protein modified form] CTD PMID:29476062 trichostatin A increases expression ISO RGD:1551009 6480464 trichostatin A results in increased expression of MAP1LC3B protein modified form CTD PMID:29476062 trichostatin A affects expression ISO RGD:1350223 6480464 trichostatin A affects the expression of MAP1LC3B mRNA CTD PMID:28542535 trichostatin A increases expression ISO RGD:1350223 6480464 trichostatin A results in increased expression of MAP1LC3B mRNA, trichostatin A results in increased expression of MAP1LC3B protein modified form CTD PMID:19606018 , PMID:20962572 trichostatin A increases cleavage ISO RGD:1350223 6480464 trichostatin A results in increased cleavage of MAP1LC3B protein CTD PMID:20543569 trifloxystrobin increases expression ISO RGD:1350223 6480464 trifloxystrobin results in increased expression of MAP1LC3B protein alternative form CTD PMID:27853101 trimethyltin decreases degradation EXP 6480464 trimethyltin results in decreased degradation of MAP1LC3B protein modified form CTD PMID:26459185 tunicamycin increases expression ISO RGD:1350223 6480464 Tunicamycin results in increased expression of MAP1LC3B protein modified form CTD PMID:20962572 tunicamycin multiple interactions ISO RGD:1551009 6480464 ATG5 protein mutant form inhibits the reaction [Tunicamycin results in increased lipidation of MAP1LC3B protein] more ... CTD PMID:29793971 tunicamycin increases lipidation ISO RGD:1551009 6480464 Tunicamycin results in increased lipidation of MAP1LC3B protein CTD PMID:29793971 tunicamycin increases prenylation ISO RGD:1350223 6480464 Tunicamycin results in increased prenylation of MAP1LC3B protein CTD PMID:20593179 urethane increases expression ISO RGD:1350223 6480464 Urethane results in increased expression of MAP1LC3B mRNA CTD PMID:28818685 valproic acid affects expression ISO RGD:1551009 6480464 Valproic Acid affects the expression of MAP1LC3B mRNA CTD PMID:17292431 , PMID:17963808 valproic acid affects expression ISO RGD:1350223 6480464 Valproic Acid affects the expression of MAP1LC3B mRNA CTD PMID:25979313 valproic acid increases expression ISO RGD:1350223 6480464 Valproic Acid results in increased expression of MAP1LC3B mRNA CTD PMID:22083351 more ... valproic acid increases expression EXP 6480464 Valproic Acid results in increased expression of MAP1LC3B mRNA CTD PMID:21318169 valproic acid increases expression ISO RGD:1551009 6480464 Valproic Acid results in increased expression of MAP1LC3B mRNA CTD PMID:20546886 , PMID:21427059 vincristine increases expression ISO RGD:1350223 6480464 Vincristine results in increased expression of MAP1LC3B mRNA CTD PMID:23649840 vorinostat affects localization ISO RGD:1350223 6480464 vorinostat affects the localization of MAP1LC3B protein modified form CTD PMID:20543569 vorinostat multiple interactions EXP 6480464 Chloroquine promotes the reaction [Vorinostat results in increased expression of MAP1LC3B protein modified form] CTD PMID:29476062 vorinostat increases expression EXP 6480464 Vorinostat results in increased expression of MAP1LC3B protein modified form CTD PMID:29476062 vorinostat increases expression ISO RGD:1350223 6480464 vorinostat results in increased expression of MAP1LC3B mRNA, vorinostat results in increased expression of MAP1LC3B protein modified form CTD PMID:20962572 , PMID:22083351 vorinostat increases cleavage ISO RGD:1350223 6480464 vorinostat results in increased cleavage of MAP1LC3B protein CTD PMID:17881280 , PMID:20543569 vorinostat multiple interactions ISO RGD:1350223 6480464 3-methyladenine inhibits the reaction [vorinostat results in increased expression of MAP1LC3B protein modified form] more ... CTD PMID:17881280 more ... wortmannin decreases expression ISO RGD:1551009 6480464 wortmannin results in decreased expression of MAP1LC3B protein CTD PMID:26847702 wortmannin multiple interactions ISO RGD:1551009 6480464 wortmannin inhibits the reaction [Rotenone results in increased expression of MAP1LC3B protein] CTD PMID:26847702 zearalenone increases expression EXP 6480464 Zearalenone results in increased expression of MAP1LC3B protein CTD PMID:31586597 , PMID:32858132 zinc atom multiple interactions ISO RGD:1350223 6480464 [PCI 5002 co-treated with Zinc] results in increased expression of MAP1LC3B mRNA CTD PMID:18593933 zinc oxide multiple interactions ISO RGD:1551009 6480464 MAP1LC3B mutant form inhibits the reaction [Zinc Oxide analog results in increased cleavage of CASP3 protein] CTD PMID:24614525 zinc oxide increases expression ISO RGD:1350223 6480464 Zinc Oxide results in increased expression of MAP1LC3B protein CTD PMID:29289694 zinc(0) multiple interactions ISO RGD:1350223 6480464 [PCI 5002 co-treated with Zinc] results in increased expression of MAP1LC3B mRNA CTD PMID:18593933
